New study observes how breast cancer patients fare on Triple-Drug therapy
NCT ID NCT07151911
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This observational study follows 100 high-risk early breast cancer patients who are already taking a combination of abemaciclib, olaparib, and endocrine therapy as part of their routine care. Researchers will track which treatments are chosen and how patients' quality of life changes over 5 years. The goal is to describe real-world patterns, not to test a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliero Universitaria Policlinico di Modena
RECRUITINGModena, Modena, 41124, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abemaciclib, olaparib, and endocrine therapy
What this could lead to
If successful, this study could help doctors better understand which high-risk early breast cancer patients benefit most from specific drug combinations, improving personalized treatment decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and real-world variability.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.